Remote Symptom Monitoring With a Wearable Device During Cancer Immunotherapy
Tests remote symptom monitoring in adults having immunotherapy for cancer, including melanoma.
Key facts
- Who runs it
- University of Pittsburgh
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Investigating Real-Time Immunotherapy Symptoms Study
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 17 Jun 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Digital remote monitoring intervention
- Usual Care
- Record updated
- 4 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma who are getting immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center. It tests remote symptom monitoring during treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma, treated with immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center
- Earlier treatment
- Must be receiving immune checkpoint inhibitor therapy for melanoma
Main reasons for not taking part
- Under 18 years old
- Cannot read and write in English
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma
- age 18 years or older
- ability to read and write in English
- owns and uses a smartphone capable of running study applications
Who cannot take part
- under 18 years old; and
- unable to read and write in English
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Carissa A LowTaking people
About the trial
What the trial wants to find out
The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are:
Read full original descriptionShow less
* Is the digital remote patient monitoring tool feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment?
Participants will:
* Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * As feasible: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
If participant is randomly assigned to the intervention group, they will also:
* Complete weekly symptom ratings via digital remote patient monitoring tool * Wear a Fitbit activity tracker as feasible for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study.
The 2 groups in the trial
- Digital remote monitoring group (intervention)Treatment being tested
Participants will complete baseline, midpoint, and end of study measures and complete the Short Physical Performance Battery (SPPB) as feasible. Participants will rate symptoms weekly for 90 days using PRO-CTCAE questions to assess symptoms commonly associated with immune-related adverse events (irAEs). Participants will also wear a Fitbit activity tracker (Inspire 3 or similar) as feasible for the duration of the study and install the Fitbit app on their smartphone. The Fitbit is a wristwatch-sized waterproof device that assesses heart and breathing rates, physical activity, and sleep, skin temperature, and oxygen levels and wirelessly transmits data to the server. Data from the wearable devices along with electronic patient-reported outcomes will be used to detect and triage immune-related adverse events.
Treatment: Digital remote monitoring intervention
- Usual careExisting treatment, for comparison
This group will complete baseline, midpoint, and end of study measures and complete the Short Physical Performance Battery (SPPB) as feasible but will not wear an activity tracker or rate weekly symptoms.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Digital Remote Patient Monitoring and Triage During Cancer Immunotherapy
- Plain-language title
- Remote Symptom Monitoring With a Wearable Device During Cancer ImmunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 August 2026